News
Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...
AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...
3d
MedPage Today on MSNGot Patients With Refractory axSpA or PsA? Consider This OptionIL-17 inhibitors are approved for axial spondyloarthritis and psoriatic arthritis, but their effectiveness in heavily ...
Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...
Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...
Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...
Explore more
Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.
MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for ...
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
3h
24/7 Wall St. on MSN4 High-Yield Blue-Chip Pharmaceutical Giants Offer Huge Total Return PotentialHere are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.
According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...
ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, has appointed Ellen Lubman, MBA as Chief Business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results